Skip to main content
Suphamai Bunnapradist, MD, Nephrology, Los Angeles, CA

Suphamai Bunnapradist MD

Kidney & Pancreas Transplantation


Professor, Medicine, UCLA School of Medicine

Join to View Full Profile
  • 200 UCLA Medical Plz Ste 565cLos Angeles, CA 90095

  • Phone+1 310-267-2555

  • Fax+1 310-206-3607

Dr. Bunnapradist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Nephrology, 1998 - 1999
  • Tufts Medical Center
    Tufts Medical CenterFellowship, Nephrology, 1996 - 1998
  • Columbus Hospital
    Columbus HospitalResidency, Internal Medicine, 1993 - 1996
  • Chulalongkorn University Faculty of Medicine
    Chulalongkorn University Faculty of MedicineClass of 1993

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1998 - 2028
  • IL State Medical License
    IL State Medical License 1995 - 1996
  • Nephrology
    American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
    PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJTJuly 24th, 2025
  • Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference
    Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect ConferenceJune 4th, 2021
  • Natera Announces Data from the ProActive Study That Supports Prospera(TM) Kidney as an Early Indicator of Transplant Rejection
    Natera Announces Data from the ProActive Study That Supports Prospera(TM) Kidney as an Early Indicator of Transplant RejectionJune 6th, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: